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Abstract Ultra-performance liquid chromatography com-
bined with time-of-flight mass spectrometry (UPLC–ToF-MS)
has been used for screening and quantification of more than
100 veterinary drugs in milk. The veterinary drugs represent
different classes including benzimidazoles, macrolides, pen-
icillins, quinolones, sulphonamides, pyrimidines, tetracylines,
nitroimidazoles, tranquillizers, ionophores, amphenicols and
non-steroidal anti-inflammatory agents (NSAIDs). After
protein precipitation, centrifugation and solid-phase extraction
(SPE), the extracts were analysed by UPLC–ToF-MS. From
the acquired full scan data the drug-specific ions were
extracted for construction of the chromatograms and evalua-
tion of the results. The analytical method was validated
according to the EU guidelines (2002/657/EC) for a quanti-
tative screening method. At the concentration level of interest
(MRL level) the results for repeatability (%RSD<20% for
86% of the compounds), reproducibility (%RSD<40% for
96% of the compounds) and the accuracy (80–120% for 88%
of the compounds) were satisfactory. Evaluation of the CCβ
values and the linearity results demonstrates that the
developed method shows adequate sensitivity and linearity
to provide quantitative results. Furthermore, the method is
accurate enough to differentiate between suspected and
negative samples or drug concentrations below or above
the MRL. A set of 100 samples of raw milk were screened
for residues. No suspected (positive) results were obtained
except for the included blind reference sample containing
sulphamethazine (88 μg/l) that tested positive for this
compound. UPLC–ToF-MS combines high resolution for
both LC and MS with high mass accuracy which is very
powerful for the multi-compound analysis of veterinary
drugs. The technique seems to be powerful enough for the
analysis of not only veterinary drugs but also organic
contaminants like pesticides, mycotoxins and plant toxins
in one single method.
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Introduction
Incorrect use of drugs in veterinary practice may leave
residues in edible tissues. These residues may have direct
toxic effects on consumers e.g. allergic reaction in hypersen-
sitive individuals, or for example antibiotics may cause
problems indirectly through induction of resistant strains of
bacteria. The EU has set maximum residue limits (MRLs) for
a variety of veterinary drugs in tissues, milk and eggs [1]. In
order to detect such residues in food and tissues, microbi-
ological or bioassay techniques are widely used as screening
methods. These methods generally do not distinguish
between members of a class of antibiotics, but provide a
semiquantitative estimate of ‘total’ residues detected. Never-
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theless, they continue to be used because of their simplicity
and low cost.
The cost-effectiveness of analytical procedures is be-
coming an important issue for all laboratories involved in
residue analysis. A way to improve cost-effectiveness is to
maximise the number of analytes that may be determined
by a single procedure or from a single portion of test
material. Such an approach is extremely effective when
multi-compound techniques, such as liquid chromatography
in combination with triple-quadrupole mass-spectrometric
detection (LC–QqQ-MS) are used. However, most reported
multi-compound methods target a few closely related com-
pounds, usually belonging to a single drug class [2, 3]. There
are a few procedures describing methods that can analyse
compounds from unrelated classes of drugs [4–6]. However,
increasing the number of analyte peaks to be monitored
beyond 100–120, requires multiple injections or monitoring
specific transitions at a specific retention time window [7].
Methods based on retention time windows, require frequent
readjustments due to small shifts of retention times. An
attractive alternative is the use of a full mass scan MS
technique, for example by using time-of-flight (ToF)MS. The
medium to high resolution of ToF-MS of 10,000 FWHM
effects a significant selectivity and therefore sensitivity gain
compared with unit-resolution scanning MS instrumentation.
An advantage of ToF-MS is that no a priori hypothesis about
the presence of certain drugs is required; that is, no analyte-
specific transitions have to be defined, as is necessary before
injecting a sample onto an LC–QqQ-MS using multiple
reaction monitoring (MRM). The high-resolution, full scan
data permit the testing of any a posteriori hypotheses by
extracting any desired exact mass chromatogram. Moreover,
the accurate mass capability of LC–ToF-MS allows the
reconstruction of highly selective accurate mass chromato-
grams of target residues in complex matrices. Accurate mass
determination and calculated elemental composition data can
be used for structure elucidation as well [8].
In the multi-compound method using the full scan MS,
the LC part of the system sometimes causes certain
limitations. Due to the high number of compounds to be
separated the run times will become relatively long. Novel
low-dead-volume, high-pressure (1,000 bar) LC equipment
provides strategies to improve resolution while maintaining
or even shortening run times. This technique is called ultra-
performance LC (UPLC). An essential aspect of the UPLC
concept is the use of sub-2-μm particulate packing materials,
while maintaining other aspects of the column geometry, e.g.
column length. UPLC–ToF-MS provides significant advan-
tages concerning selectivity, sensitivity and speed. The
higher resolution provided by UPLC is an important factor
to compensate for the fact that the selectivity of currently
available ToF-MS instrumentation is still less than that
provided by monitoring MS→MS transitions.
A very interesting example of the use of UPLC combined
with full scan mass MS for multi-compound screening of
veterinary drugs in urine is described by Kaufmann et al. [9].
The method covers more than 100 analytes belonging to
different classes of veterinary drugs. The quantification limits
were <10μg/l for over 90% of the 108 tested veterinary drugs
and metabolites.
This paper describes the validation of a comprehensive
screening and quantification method based on UPLC–
ToF-MS for the analysis of 101 veterinary drugs in milk.
The selected veterinary drugs represent 12 classes of drugs.
The benzimidazoles belong to the group of anthelmintic
drugs acting primarily against lungworms and liver fluke.
The penicillins, macrolides, quinolones, sulphonamides,
tetracyclines and amphenicols are different classes of anti-
biotics. The nitroimidazoles and ionophores are frequently
used as feed additives for the treatment and prevention of
certain bacterial and protozoal diseases. Finally the tranquil-
lizers and the non-steroidal anti-inflammatory agents
(NSAIDs) are included in the method. Milk was selected
because it is an important matrix for residue control which
can contain residues from different classes of veterinary
drugs. UPLC–ToF-MS was used to screen a series of milk
samples for drug residues. Both qualitative and quantitative
results obtained during validation and the results obtained by
the analysis of 100 different samples of raw milk will be
presented and discussed.
Materials and methods
Chemicals, reagents and solutions
Veterinary drug analytical standards were purchased from
Sigma-Aldrich Chemie b.v (Zwijndrecht, the Netherlands)
SmithKline Beecham (Zeist, the Netherlands), Riedel-de Haen
(Seelze, Germany) or Fluka (Buchs, Switzerland). Oxfendazole
and oxfendazole sulfone were purchased from Syntex (Clare
Castle, Co Clare, Ireland), valnemulin from Novartis (Basel,
Switerzerland) and marbofloxacin from Vetoquinol (New
Jersey, VS). Albendazole (sulfoxide), hydroxyipronidazole,
carazolol, propyphenazone and piroxycam were obtained from
Bundesamt fur Verbraucherschutz und Lebensmittelsicherheit,
BVL-CRL (Berlin, Germany). 5-Hydroxythiabendazole was
obtained from The National Institute for Public Health and
the Environment, RIVM-CRL (Bilthoven, the Netherlands).
Figure 1 presents the structures of a subset of the veterinary
drugs studied.
Individual veterinary drug stock solutions (0.1, 1 or
2 mg/ml; azaperone 10 μg/ml) were prepared in pure
methanol or acetonitrile and were stored at −18 °C. The
mixed standard solution was stored at −18 °C and was used
for 1 week. Sub-portions of the mixed standard solution are
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stored at −80 °C; every week a portion of this mixed standard
solution was taken and used for analysis. The penicillins are
not very stable drugs and these compounds were therefore
added to the mixed standard solution just before analysis.
The selected compounds, see Table 1, comprise the major
classes of veterinary drugs that are commonly used to treat
diseases in veterinary practice. Cinchophen (C16H11NO2;
retention time (Rt)=3.99 min) and nigericine (C40H67O11;
Rt=8.44 min) sodium salt were used as the internal stan-
dards. The internal standards were not used for recovery
corrections but for monitoring the efficiency of the extraction
procedure and to monitor the run-to-run differences in
retention times. LC/MS-grade acetonitrile, water and meth-
anol were obtained from Biosolve (Valkenswaard, the
Netherlands). Formic acid was obtained from Merck.
Solid-phase extraction columns (Strata-X 33-μm polymeric
reversed-phase 60 mg/3ml) were obtained from Phenomenex
(Torrance, CA, USA).
Samples
All milk samples tested were raw (not pasteurised) milk
samples collected by the Dutch Food and Consumer Product
Safety Authority, Laboratory Region East (Wageningen,
The Netherlands), at farmhouses during the spring of 2007.
The samples were received frozen and were kept frozen
(−20 °C) until analysis.
The reference sample of milk used was previously used in
a proficiency test organized by Progetto Trieste (Laboratory
Proficiency Testing for Food Analysis; Italy). The sample
was coded Progetto/2007/Mi329A. The assigned value was
87.8 μg/l sulphamethazine (=sulphadimidine).
Instrumentation
Liquid chromatography
The separation of the veterinary drugs from the raw milk
extracts was carried out using an ultra-performance liquid
chromatography (UPLC) system, consisting of a vacuum
degasser, autosampler and a binary pump (Acquity UPLC
system; Waters, Milford, MA) equipped with a reversed-
phase Waters acquity UPLC BEH C18 analytical column
of 50×2.1 mm and 1.7-μm particle size. The gradient
(solvent A, water/formic acid (1,000:1, v/v); solvent B, water/
acetonitrile/formic acid (100:900:1, v/v/v)) was 0 min, 0% B;
1–6 min, linear increase to 40% B; 6–7.5 min linear increase
to 100% B with a final hold for 1 min. Injection volume was
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Fig. 1 Structures of representative compounds from each class of drug studied
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Table 1 Characteristics and validation results obtained for the studied 101 veterinary drugs in milk (concentration 1×VL)
Compound Rt
(min)
[M+H]+
(m/z)
Δppma MRL VLb
(μg/l)
Intra-day
%RSD
Inter-day
%RSD
Acc.
(%)
CCβ
Benzimidazoles
Albendazole 4.72 266.0963 0.0 100 50 6.1 9.1 99 64.9
Albendazole sulfoxide 3.23 282.0912 4.6 100 50 7.0 7.8 90 61.5
Albendazole sulfone 3.78 298.0862 −3.7 100 50 5.8 6.6 99 60.8
Albendazole aminosulfone 2.46 240.0807 −2.9 100 50 5.5 5.9 113 61.0
Fenbendazole 5.64 300.0806 11.7 10 10 3.1 7.1 112 12.6
Oxfendazole 3.94 316.0756 4.7 10 10 3.4 5.3 108 11.9
Oxfendazole sulfone 4.65 332.0705 5.4 10 10 3.9 7.3 106 12.5
Mebendazole 4.71 296.1035 19.9 –c 2 5.6 9.4 108 2.7
Aminomebendazole 3.6 238.0980 9.2 – 2 8.2 9.5 100 2.6
Hydroxymebendazole 3.61 298.1192 2.3 – 2 7.7 7.7 100 2.5
Levamisole 2.31 205.0799 2.4 – 2 7.5 19.9 133 3.7
Thiabendazole 2.48 202.0439 −12.4 100 50 7.2 8.8 168 74.2
5-Hydroxythiabendazole 2.32 218.0388 −4.6 100 50 10.6 11.4 139 76.1
Flubendazole 4.98 314.0941 6.7 – 2 5.6 8.1 102 2.5
Aminoflubendazole 3.8 256.0886 10.2 – 2 5.3 8.5 105 2.6
Hydroxyflubendazole 3.84 316.1097 −4.4 – 2 6.7 11.2 99 2.7
Oxibendazole 3.9 250.1191 −2.0 – 2 6.3 6.7 110 2.5
Macrolides
Erythromycin 5.06 734.4690 0.8 40 40 3.9 8.6 100 51.3
Spiramycin 4.08 843.5218d −5.5 200 50 4..4 7.6 116 64.4
Tilmicosin 4.68 869.5738d −4.4 50 50 3.9 5.7 104 59.7
Tylosin 5.40 916.5270 −5.1 50 50 3.7 7.3 113 63.5
Josamycin 6.14 828.4745 3.6 – 50 5.5 9.2 109 66.4
Tiamulin 5.45 494.3304 4.2 – 50 5.2 6.4 112 61.8
Valnemulin 6.01 565.3675 14.3 – 50 6.1 9.9 112 68.2
Lincomycine 2.59 407.2216 2.7 150 50 20 32.5 157 134
Pirlimycine 3.93 411.1720 1.2 100 50 17.3 18.7 104 81.9
Tulatromycine 3.4 806.5742d −7.4 – 50 14.4 19.7 106 84.2
Penicillins
Penicillin V 5.38 351.1014 19.4 – 25 9.0 13.3 108 36.8
Ampicillin 2.79 350.1174 13.4 4 25 29.8 33.8 124 59.3
Oxacillin 5.67 402.1123 0.2 30 30 7.4 10.9 108 41.6
Nafcillin 6.29 415.1327 −1.4 30 30 34.0 34.8 76 56.0
Cloxacillin 6.05 436.0734 24.5 30 30 18.4 25.0 112 57.5
Dicloxacillin 6.53 470.0330 5.5 30 30 6.7 8.6 105 38.9
Quinolones
Nalidixic acid 4.71 233.0926 7.7 – 2 6.7 11.3 104 2.8
Oxolinic acid 3.99 262.0715 6.1 – 2 5.5 5.7 104 2.4
Flumequine 4.99 262.0879 -3.8 50 50 3.2 11.1 101 68.3
Norfloxacin 2.92 320.1410 3.1 – 25 10.9 15.0 121 39.9
Ciprofloxacin 3 332.1410 6.6 – 5 11.2 12.7 103 7.1
Lomefloxacin 3.11 352.1472 4.0 – 5 7.5 13.7 102 7.3
Enrofloxacin 3.22 360.1723 −4.7 100 50 26.3 27.2 102 95.5
Marbofloxacin 2.79 363.1468 0.8 75 50 9.3 14 113 75.9
Difloxacin 3.46 400.1472 3.7 – 2 7.0 8.1 102 2.5
Danofloxacin 3.15 358.1567 5.0 30 30 7.3 7.8 121 39.2
Sarafloxacin 3.42 386.1316 6.7 – 5 7.6 12.0 102 7.0
Sulphonamides
Dapsone 3.01 249.0697 2.0 5e 5 11.9 19.7 113 8.7
Sulphadiazine 2.02 251.0602 1.6 100 50 6.3 6.6 91 59.9
Sulphamethoxazole 3.42 254.0599 2.0 100 50 6.9 7.9 119 65.4
Sulphamethazine 2.85 279.0915 −4.7 100 50 4.5 11.7 102 69.6
Sulphadimethoxine, 3.53 311.0814 7.1 100 50 6.1 9.6 102 66.1
Sulphadoxine 4.24 311.0814 −1.0 100 50 4.9 7.9 101 63.0
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Table 1 (continued)
Compound Rt
(min)
[M+H]+
(m/z)
Δppma MRL VLb
(μg/l)
Intra-day
%RSD
Inter-day
%RSD
Acc.
(%)
CCβ
Sulphaquinoxaline 4.32 301.0759 −2.3 100 50 5.5 5.7 108 60.0
Sulphachloropyridazine 3.22 285.0213 8.4 100 50 6.9 7.1 106 62.3
Sulphamerazine 2.47 265.0759 1.1 100 50 5.9 9.0 113 66.7
Sulphamethizole 2.89 271.0323 0.0 100 50 4.4 6.1 87 58.7
Sulphamethoxypyridazine 2.96 281.0708 1.1 100 50 6.4 6.4 112 61.7
Sulphamonomethoxine 3.22 281.0708 0.7 100 50 4.1 6.9 110 62.5
Sulphamoxole 3.69 268.0756 5.6 100 50 6.6 10.3 90 65.2
Sulphapyridine 2.38 250.0650 4.8 100 50 7.1 11.9 112 71.9
Sulphisoxazole 2.84 268.0756 2.2 100 50 32f 36.0f 107 113
Sulphathiazole 2.31 256.0214 3.5 100 50 5.3 11.0 107 69.3
Pyrimidines
Trimethoprim 2.77 291.1457 3.3 50 25 9.3 14.4 111 38.1
Tetracyclines
Tetracycline 3.04 445.1611 2.9 100 100 8.0 11.1 82 130
Doxycycline 4.05 445.1611 3.8 – 100 9.8 10.2 90 130
Oxytetracycline 2.82 461.1560 −1.1 100 100 7.4 12.1 92 136
Chlorotetracycline 3.77 479.1221 −0.6 100 100 5.1 15.9 80 142
Nitroimidazoles
Ipronidazole 3.31 170.0930 0.6 – 5 30.4 39.6 186 17.1
Hydroxyipronidazole 2.85 186.0879 3.8 – 5 14.0 14.5 114 7.7
Tranquillizers
Azaperol 2.83 330.1982 0.0 – 1 6.8 10.2 116 1.4
Azaperone 3.11 328.1825 4.3 – 1 7.7 12.3 102 1.4
Propionylpromazine 5.59 341.1688 14.1 – 1 54f 58f 98 2.9
Acetopromazine 5.06 327.1531 5.5 – 1 26f 26f 97 1.8
Xylazine 3.22 221.1112 −1.4 – 1 6.4 12.0 101 1.4
Haloperidol 4.92 376.1480 6.1 – 1 4.8 6.3 96 1.2
Chloropromazine 5.75 319.1036 4.4 – 2 NDg ND ND ND
Carazolol 3.94 299.1760 4.7 – 1 6.7 7.0 112 1.3
NSAIDs
Piroxycam 4.92 332.0705 3.3 – 50 8.7 9.5 112 67.4
Propyphenazone 5.09 231.1497 −7.4 – 20 2.8 7.0 105 24.8
Indoprofen 5.52 282.1130 13.5 – 20 10.5 10.8 107 27.6
Tolmetin 5.93 258.1130 25.6 – 50 13.2 13.7 115 75.9
Ketoprofen 6.09 255.1021 32.5 – 50 12.5 13.9 120 77.3
Naproxen 6.12 231.1021 10.4 10e 50 12.7 13.8 114 75.8
Fenbufen 6.39 255.1021 13.7 – 50 8.9 9.4 106 66.3
Carprofen 6.75 274.0635 12.8 – 50 14.1 14.6 104 75.0
Diclofenac 6.82 296.0250 10.8 5e 50 8.8 9.2 105 65.8
Niflumic acid 6.66 283.0694 12.4 – 50 5.0 9.0 102 65.0
Phenylbutazone 6.91 309.1603 6.8 5e 25 48.8f 55.0f 135 85.9
Flufenamic acid 7.02 282.0742 5.0 – 50 11.8 14.5 87 70.8
Mefenamic acid 7.03 242.1181 −8.3 10e 50 14.1 15.4 97 74.6
Meclofenamic acid 7.04 296.0250 11.8 – 50 16.9 23.9 81 81.8
Isopyrin 2.59 246.1606 0.0 – 50 33.0f 34.0f 119 116
Isoxicam 6.34 336.0654 6.2 – 50 4.8 5.0 114 59.4
Tenoxicam 3.91 338.0269 5.3 – 50 9.5 11.7 107 70.5
Sulindac 5.78 357.0961 5.3 – 50 11.7 12.6 111 73.0
Indomethacin 6.85 358.0846 3.1 – 50 27.3 35.5 86 100
Flunixin 5.65 297.0851 6.1 50 50 3.7 6.5 99 60.6
Ionophores
Monensin Na 7.84 693.4190 −3.7 2 1 16.0 27.3 119 2.1
Salinomycine Na 7.91 773.4816 −10.9 – 1 56.2f 57.5f 97 3.6
Narasin Na 8.05 787.4972 −7.5 – 1 26.9f 27.3f 93 1.9
Maduramycine Na 8.07 934.5739 −14.2 – 1 9.4 20.2 100 1.7
Anal Bioanal Chem (2008) 391:2309–2322 2313
40μl. The flow rate was 800μl/min andwas split (1:7) before
entering the ToF.
LC–electrospray time-of-flight mass spectrometry
The UPLC system was connected to a time-of-flight
mass spectrometer Waters-Micromass LCT Premier ToF
equipped with an electrospray interface operating in the
positive ion mode, using the following parameters: cone
voltage, 50 V; capillary voltage, 2,800 V. Full scan spectra
from 100 to 1,000 Da were acquired with a scantime of
0.2 s. Mass accuracy was maintained by using a lock
spray with lock mass of leucine-enkefaline 12C [M+H]+ ion
m/z 556.2771. Resolution was at least 10,000 FWHM at
m/z of the lock mass. Dynamic range enhancement (DRE)
was switched on.
Sample pre-treatment and extraction
The milk (2 ml) was mixed with acetonitrile (2 ml) to effect
precipitation of proteins. After an intensive shaking period
of 30 min, the samples were centrifuged for 15 min
(3,600 g at T=10 °C). From the supernatant 2 ml was
diluted ten times with water. The diluted sample was
applied to a StrataX-SPE column. The column was con-
ditioned with 3 ml methanol and 3 ml water and washed
with 3 ml water. The analytes were eluted with 3 ml
methanol.
UPLC–ToF-MS analysis
After evaporation of the StrataX eluate under a stream of
nitrogen at 40 °C, the dried extract was redissolved in 50 μl
acetonitrile and vortexed for 30 s. Next 450 μl water/formic
acid (1,000:2, v/v) was added and an aliquot of 40 μl was
analysed by UPLC–ToF-MS in the full scan mode. After
acquisition the specific [M+H]+ ions (see Table 1) were
extracted from the spectra. The used extraction mass window
width was drug specific and ranged from 10 to 200 mDa.
Quantification
For quantification, a detector response (peak areas) versus
concentration plot was constructed. To this end, five blank
milk samples were fortified with different concentrations of
the specific drug. The real milk samples were analysed
together with the calibration samples (matrix-matched
standards or MMS); concentrations were calculated using
the linear regression method.
Validation
The developed method was validated based on the pro-
cedure described in ref. [10] for quantitative screening. The
following characteristics have to be determined: repeatabil-
ity, within-lab reproducibility, accuracy, linearity, CCβ,
selectivity/specificity, robustness and stability. CCβ is
defined as the smallest content of the substance that may
be detected, identified and/or quantified in a sample with an
error probability of β (in this study β=5%).
Repeatability, within-lab reproducibility, accuracy
The validation study for the quantitative screening of
veterinary drugs in milk was carried out at three concen-
tration levels viz. 0.5–1.0–1.5 times the validation level
(VL), defined in this paper as the MRL or recommended
concentration level recommended by EU Community
Reference Laboratories [10]. For drugs without an MRL
or recommended concentration level a specific level of
interest was defined based on the drug characteristics (class
of compounds) or based on MRL or recommended con-
centration level of the specific drug in other matrices like
liver, kidney or meat. All concentration levels used for the
validation study are described in Table 1. For some
compounds the VL was at a slightly higher level than the
MRL or recommended level due to the limited sensitivity of
the ToF detector for that specific drug. Some compounds
are validated at a concentration level below the MRL or
Table 1 (continued)
Compound Rt
(min)
[M+H]+
(m/z)
Δppma MRL VLb
(μg/l)
Intra-day
%RSD
Inter-day
%RSD
Acc.
(%)
CCβ
Amphenicols
Florphenicol NH4 3.52 358.0083 15.4 – 5 26.9 28.5 122 10.7
Thiamphenicol NH4 2.76 356.0126 −0.3 50 50 12.1 15.1 115 78.5
aΔppm differences between theoretical exact mass and measured mass
bVL validation level; the validation results presented: intra-day, inter-day, accuracy and CCβ are obtained for 1×VL (see also text)
c – compound with no defined MRL or recommended concentration level
d [M+2H]2+ ion is detected
e By EU Community Reference Laboratories (CRLs) recommended concentration level
f Validation study based on n=14 (2 validation days); all other results are based on n=21 (3 validation days)
gND not determined; selected concentration levels are too low for quantification
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recommended level to prevent the amount of compound
detected being outside the range for which the ToF is linear.
Blank samples of milk were fortified with a specific
concentration of drug and seven replicates of each sample
were analysed on 1 day. The procedure was repeated on
two additional days.
From the data obtained intra-day repeatability, within-lab
(inter-day) reproducibility and accuracy were calculated.
Preferably the minimum %RSD for the repeatability and the
within-lab reproducibility have to be as described in Table 2
[11]. The accuracy, i.e. (detected concentration divided by
added concentration)×100%, preferably has to be within
the 70–120% range. This range is set for this study as an
acceptable accuracy for a multi-compound quantitative
screening method for the concentration range 1–150 μg/l.
Linearity
The linearity was determined for a concentration range of
0–0.25–0.5–1–2 and 4 times the VL. On each validation
day the calibration curves were constructed by means of
plotting the detection response of the matrix-matched
standard solutions versus the concentrations by means of
regression analysis. From these data the regression coef-
ficients (R2) of the calibration curves were calculated. The
criterion for good linearity was R2>0.99.
CCβ and LOQ
The detection capability (CCβ) at the VL was determined
as follows: the CCβ=CCα+1.64×sd(at VL) (sd = standard
deviation of within-lab reproducibility) in which CCα=
VL+1.64×sd(at VL).
Additionally to the CCβ the limit of quantification (LOQ)
was determined by analysing seven samples of milk fortified
at the concentration level of 1/8×VL. In cases where the
signal/noise at this concentration was ≥6, 1/8×VL was set
as the LOQ; otherwise the next calibration level with signal/
noise ≥6 was set as the LOQ.
Robustness
The robustness of the method was tested by analysing four
samples of milk in duplicate and for each sample the
sample pre-treatment/extraction procedure was slightly
different. The first sample was analysed by using the
developed procedure. For the second sample the extraction
time was extended from 30 to 60 min. For the third sample
the centrifugation step was at 3,600 rpm instead of 3,600 g.
For the fourth sample the final residue after evaporation of
the solvent was kept dry for 30 min before resolution. The
method is robust in the case the %RSD of a specific
compound within these eight analyses ≤ %RSD of the
corresponding within-lab reproducibility.
Specificity
The specificity of the method was checked by the analysis
of 20 blank samples. The chromatograms were monitored
for peaks interfering with those of the drugs of interest.
Stability
No stability experiments were performed in this study.
The stability data were obtained from previous studies
carried out for the specific classes of drugs during the
validation study of the LC–QqQ-MS methods. From these
studies it is known that all compounds of interest were
stable for at least 1 month with the exception of the peni-
cillins. Penicillins are not very stable and their standard
solutions have to be prepared right before the validation
experiments.
Sample analysis
The samples of raw milk were analysed in four series of 25
samples each. Each series of samples started and ended
with the analysis of the matrix-matched calibration stan-
dards. The samples were analysed by the method and the
experimental conditions as described above.
The criteria for acceptance of the analytical results were:
– Sensitivity check (signal noise at LOQ level ≥6)
– Deviation of r of the two calibration curves ≤20%
– Relative retention time of suspected analyte and
reference standard within the tolerance interval of
±2.5%
– Criterion for good linearity: R2>0.99
In the case of a suspected result (positive response) the
sample was reanalysed for the specific compound(s). A
suspected result is obtained when the response measured
for an MRL substance is at or above the CCβ level and for
all other substances at or above the LOQ level. The
confirmatory analysis is based on an LC–QqQ-MS method
monitoring two product ions of the suspected compound(s)
thereby fulfilling the criteria described by the guidelines
[11] for confirmatory analysis.
Table 2 Guidelines (%RSD) for repeatability and within-lab repro-
ducibility [11]
Concentration
(μg/l)
Repeatability
%RSD
Within-lab
reproducibility %RSD
100 11 23
10 16 32
1 22 45
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Results
General considerations
Sample pre-treatment
Different sample pre-treatment/extraction approaches for
the determination of residues of drugs in milk are described
in the literature and are in use in our laboratory. Possible
approaches are liquid/liquid extraction (LLE), solid-phase
extraction (SPE), combination of LLE and SPE, ultrafiltra-
tion, etc. [4]. For the described multi-compound method the
sample pre-treatment step has to be very generic. Therefore
ultrafiltration and polymer-based C18-SPE columns (Oasis
and StrataX) were tested. The use of ultrafiltration did not
show satisfactory recoveries. The use of SPE resulted (due
to less matrix interferences and a concentration step) in
higher accuracies and lower detection limits. It is obvious
that by introduction of an SPE-C18 step the very polar
compounds will not be recovered; however, on the other
hand by using SPE the extract is concentrated which makes
it possible to also detect prohibited compounds at very low
levels. The recovery results obtained by using the StrataX
SPE column were 5–10% higher (depending on the analyte)
than those obtained for the Oasis SPE; therefore the StrataX
SPE column is used for the multi-screening method.
UPLC–ToF-MS screening method
The UPLC–ToF-MS full scan accurate mass screening
procedure enables the analysis of more than 100 veterinary
drugs and metabolites. The main advantage of the proposed
approach is the theoretically unlimited number of compounds
to be screened simultaneously at low concentration levels.
To construct the screening method, a solvent-based stan-
dard with the mixture of studied veterinary drugs was
analysed. The method is constructed based on the retention
times and responses at specific accurate masses. In the method
the different combinations of retention time and accurate mass
are defined with their respective acceptable tolerances. After
analysis of a real sample the full scan chromatogram is
processed and thereby a list of detected compounds (included
in the screening method) is generated. A big advantage of the
UPLC–ToF-MSmethod is that not all compounds of interest a
priori have to be defined. If later in time a specific compound
becomes of interest (which was not included in the screening
method) the collected full scan spectra is reprocessed and
checked for presence of that specific new compound.
QqQ MS confirmation method
For each class of drug, analytical methods are available for
the quantification and identification based on LC–QqQ-MS
[4, 12]. By the use of the UPLC–ToF-MS technique a real
multi-compound method including different classes of
drugs becomes available. For the confirmation of identity
of veterinary drugs in products of animal origin the criteria
as described in ref. [11] for confirmation have to be met.
The confirmation is based on the collection of so-called
identification points (IPs). For the confirmation of the
identity of unauthorised substances a minimum of four IPs
is required. For the confirmation of the identity of MRL
substances a minimum of three IPs is required. The number
of IPs earned by a specific analysis depends on the
technique used. However, almost invariably these tech-
niques have to be based on mass spectrometric detection. A
low-resolution mass spectrometer, such as a QqQ or an ion-
trap (IT), is able to acquire 1.0 IP for the precursor ion and
1.5 IPs for each product ion; that is, with the selection of
two multi-reaction-monitoring (MRM) transitions, 4.0 IPs
are acquired. The mass accuracy of a high-resolution mass
spectrometer (resolution ≥20,000 FWHM) acquires 2.0 IPs
for the precursor ion and 2.5 for each product ion, so, in
this case, the IPs acquired in the product ion scan mode are
(2+2.5n). However identification criteria for the analysis by
ToF-MS, medium to high resolution of approximately
10,000 FWHM, are not included (yet) in the EU document
[11]. Therefore UPLC–ToF-MS is used as a quantitative
screening method. The samples suspected of containing a
drug at a concentration level above the MRL or MRPL will
be analysed by an LC–QqQ-MS method for the final
confirmation of the identity.
Accurate mass measurements
Table 1 presents the accurate mass measurement data
obtained for milk extracts. In general for a ToF having a
mass resolution of ca. 10,000 FWHM and an external
calibration, a deviation of the measured accurate mass
versus the calculated mass of 10 ppm is acceptable [13],
especially when the low concentration levels (1–150 μg/l)
are taken into account. From Table 1 we concluded that the
accurate measurements in a real sample extract are
acceptable for more than 80% of the compounds studied.
It is noted that 15 out of 21 compounds with a measured
mass deviation >10 ppm elute with a retention time
>5.5 min. Looking at the total ion current (TIC) chromato-
gram of a milk extract (Fig. 3) it is obvious that beyond
5.5 min most of the matrix compounds are eluting. For the
analysis an absolute amount of 1 ml of milk is concentrated
to a final volume of 500 μl from which 40 μl is injected,
corresponding to approximately 80 mg of matrix equivalent
per injection. For the UPLC–ToF-MS method described in
ref. [9] only 0.4 μg of matrix was injected. The unexpected
low mass accuracy for compounds eluting above 5.5 min is
probably due to elution of a large amount of matrix
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compounds [14]. However, the concentration step is
necessary to detect the unauthorised compounds at the
1 μg/l level.
Validation study
The results obtained at the different concentration levels
(0.5–1–1.5)×VL are in the same range. Therefore only the
results obtained for 1×VL are presented in Table 1. The
exceptions are discussed below.
Repeatability, reproducibility and accuracy
We concluded that at the validation level (VL) more than
65% of the compounds tested show a repeatability of RSD
<10% and less than 15% of the compounds show a
repeatability of RSD>20%. At 0.5×VL the percentages
are significantly different. At 0.5×VL almost 50% of the
compounds show repeatability results of RSD>10%.
Comparing the 1×VL and 1.5×VL levels only slightly
better results are obtained for the latter. At the 1×VL level
34 compounds show RSD>10% and only 13 compounds
show RSD>20%. Three compounds out of the group of
tranquillizers show RSD>20%, probably due to the low
concentration of interest (<5 μg/l). Furthermore the more
polar and early-eluting compounds like isopyrin and
sulphisoxazole show RSDs>20%. Overall the repeatability
results are acceptable (RSD<20%) for more than 86% of
the compounds.
From the within-lab reproducibility results we con-
cluded that 19 compounds show reproducibility results
RSD>20% at the 1×VL. There are four compounds
with unacceptably high (>40% at 1×VL) reproducibility
results. These results are obtained for two tranquillizers,
propionylpromazine and chloropromazine, for the non-
steroidal anti-inflammatory drug (NSAID) phenylbutazone
and for the ionophore salinomycine. We concluded that for
96% of the compounds the reproducibility results are
satisfactory (%RSD<40%).
From the accuracy results we concluded that 89% of the
compounds show acceptable accuracy results. There are only
a few compounds with accuracy results <80% or >120%
even at the 1×VL. Compounds with an accuracy >120% are
levamisole, (hydroxy)thiabendazole, lincomycine, ampicil-
lin, ipronidazole, phenylbutazone and florphenicol. The
compounds norfloxacin and danofloxacin show accuracies
of 121%. The compound with an accuracy (at 1×VL) <70%
is not surprisingly the unstable nafcillin. The accuracy of
chloropromazine is not established. For this compound no
accurate quantification is possible at the concentration range
of interest.
For compounds with a repeatability of RSD>20%,
reproducibility RSD>40% and/or accuracy of >120% or
<70%, accurate quantification is not possible. For these
compounds accurate quantification is only possible by
applying a standard addition procedure or after the method
has been optimized for the specific compound.
CCβ, LOQ and linearity
After evaluation of the results some general conclusions
can be drawn. The first is that for the compounds with 1×
VL between 1 and 50 μg/l the CCβ are all within the range
of 1.2–100 μg/l (see Table 1). Three drugs, lincomycine,
sulphisoxazole and isopyrin, show CCβ values of >100 μg/l
at 1×VL of 50 μg/L. For the tetracyclines the 1×VL
values are 100 μg/l and the CCβ range from 129.9–
141.8 μg/l.
For chloropromazine no CCβ is established for the
above-described reason.
The second conclusion is that the LOQ levels (not
presented here) for 93 of the 101 compounds are at or
below 1/8×VL. For azaperol and naproxen the LOQs are
1/4×VL and for isopyrin and three of the ionophores the
LOQs are 1/2×VL. For the ionophore salinomycine and for
phenylbutazone the LOQ is at 1×VL. For some drugs the
1×VL was set a little higher than the MRL or recom-
mended concentration. Taking this into account only three
NSAIDs, diclofenac, naproxen and phenylbutazone, cannot
be detected at the recommended concentration. The LOQ of
diclofenac is only slightly higher, namely 6.3 μg/l (recom-
mended 5 μg/l). The LOQ of naproxen is 12.5 μg/l
(recommended 10 μg/l) and for phenylbutazone 25 μg/l
(recommended 5 μg/l). When the LOQs are compared with
the results presented by Kaufmann et al. [9] for urine
samples (>90% of the compounds LOQ<10 μg/l) we
concluded that in this respect the presented method for milk
is even more sensitive because >90% of the compounds
tested show LOQs of <7 μg/l. It has to be mentioned that
for the presented method a SPE step was included.
Kaufmann only used a dilution step.
A third conclusion is that the regression coefficients (R2)
(not presented here) of approximately 80% of all matrix-
matched calibration curves versus concentration plots
ranged from 0.25×VL to 4×VL are >0.99. Moreover, all
curves show R2>0.9 with only three exceptions, lincomy-
cine with a R2 of 0.87, isopyrin with R2 of 0.86 and again
chloropromazine for which no R2 is established.
Robustness, specificity/selectivity
From the %RSD within the robustness samples we
concluded that the method was robust (%RSD robustness
≤%RSD within-lab reproducibility). The method is also
specific/selective, since no peaks (>LOQ) were detected in
known blank samples of milk.
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Application study
The 100 milk samples were analysed on four different days.
For all days the sensitivity and linearity checks were OK.
None of the samples was marked as suspected of containing
a veterinary compound. However the included reference
sample tested positive for sulphamethazine (Fig. 2). The
technician did not know that this reference sample was
included (blind sample). The reference sample was previ-
ously analysed by an LC-QqQ-MS method for containing
sulphonamides and tested positive for sulphamethazine
(86 μg/l assigned value 88 μg/l). With the current screening
method the concentration was approximately 82 μg/l.
All the samples (except the reference sample) were pre-
viously screened negative for the antibiotics (tetracylines,
aminoglycosides, macrolides and penicillins) by using
microbiological screening tests. Microbiological screening
tests are group specific. The UPLC–ToF-MS method is
compound specific (individual drugs are identified). Fur-
thermore it is very easily to add a new drug even from
another class of drugs to the UPLC–ToF-MS method and
retrospective analysis for a specific compound is possible
by simply reprocessing the acquired data construction of
the extracted ion chromatogram (XIC).
Hardly any differences can be observed between the total
ion chromatogram (TIC) obtained for a blank and the fortified
sample. However, looking at an example of a typical XIC of
the blank presented in Fig. 3a and the fortified sample of milk
(at 1×VL) presented in Fig. 3b the differences are clear. The
extracted ions are a representative sub-selection of the
compounds tested, including: albendazole m/z 266.0963;
thiabendazole m/z 202.0439; flumequine m/z 262.0879;
norfloxacin m/z 320.1410; enrofloxacin m/z 360.1723; sulpha-
diazine m/z 251.0602; sulphamethoxazole m/z 254.0599;
tetracycline m/z 445.1611; diclofenac m/z 296.0250.
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Fig. 2 UPLC–ToF-(ESI+)MS chromatogram of proficiency test sample of milk with a selection of extracted ion chromatograms; sample contains
sulphametazine (88 μg/l); extraction mass window 0.020 Da
Fig. 3 Typical example of a UPLC–ToF-(ESI+)MS extracted ion
chromatograms of a blank sample of milk and b blank sample fortified
at the 1×VL; extraction mass window 0.050 Da, and c=b with
extraction mass window of 0.010 Da (see text for more details)
b
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Discussion
From the literature it is known that the selected width of the
extraction mass window is important. When a very small
extraction mass window width is selected there is possible
chance of false negative results [15]. Co-elution of isobaric
compounds can result in significant deviations in exact
mass measurements. The accurate mass assigned to a peak
is the average of the accurate masses of the co-eluting
peaks. Therefore it is possible that the average accurate
mass is outside the extraction mass window width which is
set for the specific compound of interest. The final result is
a false negative observation [15]. When the extraction mass
window is set at 0.05 Da (Fig. 3a,b) all peaks are detected.
When the extraction mass window is set at 0.01 Da as
is shown in Fig. 3c, all the peaks are still detected show-
ing exactly the same abundances with thiabendazole
(m/z 202.4399) being the only exception. The thiabendazole
peak splits into two separate peaks at this low extraction
mass window width. This observation is possibly not due to
an isobaric interfering compound co-eluting with thiaben-
dazole because in the blank sample no peak is detected. It is
expected based on the shape of the peak in Fig. 3b, that this
peak shows high intensity and that the detector is over-
loaded. When this occurs the dynamic range enhancement
(DRE), which is a technical device within the ToF, will
electronically reduce the signal. This functionality does not
influence the acquired data; however, sometimes this
‘correction’ of signal results in a ‘dip’ at the top of the
peak. In summary the peak is split probably due to the effect
of the DRE.
The influence of the extraction mass window width is
more obviously demonstrated in Fig. 4. Figure 4 presents
the full scan TIC chromatogram of a sample of milk. To
find out if this sample contains oxolinic acid the XIC of the
ion m/z 262.0715 is constructed. Two peaks are detected.
Reducing the width of the extraction mass window from 1
to 0.050 Da still results in two peaks being detected, one at
Rt=3.96 min and one at Rt=4.95 min. Only when the
extraction mass window is set at 0.010 Da is one peak,
oxolinic acid, at Rt=3.96 min, detected. The peak detected at
Rt=4.95 is flumequine with an accurate mass ofm/z 262.0879.
In this typical example, also described by Kaufman for urine
samples [9], the drugs can easily be separated based on the
retention times; however when this is not the case, for
example when less selective LC is used, the two compounds
can only be separated from each other when the mass
resolution of the ToF is high enough. The ion mass differs by
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Fig. 3 (continued)
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262.0879–262.0715=0.0164 Da. The mass resolutions of the
detector in combination with mass accuracy are important
parameters for a reliable screening result [14, 16].
Some authors sometimes confuse the term extraction
mass window width and mass resolution [9]. These are two
completely different things. The mass resolution is the power
of the ToF-MS to separate two ions with only slightly
different accurate masses. The extraction mass window
width has nothing to do with MS resolution; it is just a
parameter used to present the detected ions, in other words it
defines the mass range of the ions which has to be extracted
from the acquired data to construct the chromatogram.
From the examples given above it is concluded that
UPLC–ToF-MS is a very powerful technique for multi-
compound detection and in theory for an unlimited number
of compounds [17]. Therefore in our lab research is ongoing
to use the described method not only for the determination of
veterinary drug residues but also to include other organic
residues and contaminants like pesticides, environmental
contaminants, mycotoxins and plant toxins. The first experi-
ments have been performed and the first preliminary results
obtained. The samples of milk are extracted with an
acetonitrile/formic acid mixture; after a centrifugation step
the extracts are directly injected into the UPLC–ToF-MS and
screened for more than 270 compounds. The results of this
comprehensive analysis of residues and contaminants are very
promising and will be published separately elsewhere [18].
Conclusions
There is increasing interest in methods for the simultaneous
analysis of various classes of veterinary drugs. Such multi-
compound analyses which, in one run, can deal with more
than 100 compounds are only possible by using full mass
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scan MS techniques like ToF-MS. Several examples have
already been published, with UPLC–ToF-MS probably
being the most powerful measurement tool as is also
demonstrated by the present study. The use of UPLC is
especially powerful when biological extracts have to be
screened because the additional LC selectivity compensates
for the lack of selectivity in comparison with the MS/MS
option of a QqQ-MS.
In the past, an LC–QqQ method (utilizing selected
MRM transitions) was the starting point for method
development. Today, in theory all compounds can be mea-
sured by full scan MS. The starting point now is no longer
the detection conditions used, but the sample material.
Starting with for example milk all relevant veterinary
drugs—irrespective of the class they belong to—can be
detected in one (UP)LC–ToF-MS analysis, and the most
important part of the method development is the generic
extraction of the compounds of interest out of the matrix.
This will no doubt cause an increased interest in a variety of
modern sample pre-treatment techniques. The sample pre-
treatment step becomes even more interesting when other
organic contaminants like residues of pesticides, mycotoxins
and or plant toxins are included in the comprehensive
screening method.
In summary, the UPLC–ToF-MS combination offers
unsurpassed performance for screening purposes, it can also
effectively provide concentration values, and is accurate
enough to differentiate between positive and negative
samples or drug concentrations below or above the MRL.
Finally it has to be mentioned that the confirmatory
analysis of the suspected samples has to be done by the use
of an MS/MS technique because criteria for confirmation of
the identity of drugs by ToF-MS are not included yet in the
EU guidelines.
The introduction of new MS techniques like ToF also
has consequences for the EU criteria defined for confirma-
tion of compound identity. Both mass resolution and mass
accuracy data are of influence for such identity confirma-
tion and both parameters should preferably be included in
the revised version of Commission Decision 2002/657/EC.
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